$SI

Ahearn Matthew Fraser sold $465K of SI

Ahearn Matthew Fraser (Chief Operating Officer) sold 22,500 shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $20.66 ($20.10–$21.38, $0.46M total) across 3 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ahearn Matthew Fraser
Published Aug 18, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SI
Neutral
medium confidence
Mentioned
$SI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SINeutralLow
01

Why it matters

For trading, the key incremental information is the newly filed insider sale size, price range, and post-transaction holdings. However, the 10b5-1 designation generally lowers the informational content about near-term fundamentals.

02

Market read

New insider-sale disclosure for SI, likely to have limited fundamental impact but may influence short-term sentiment/positioning.

03

What to watch

The filing does not indicate whether other insiders or the company itself are buying, nor does it provide performance context; traders should treat it as sentiment noise unless paired with other catalysts.

Relevance 3/10Novelty 6/10Timing: SEC Form 4 filed 2026-08-18, covering sales dated 2026-08-17 to 2026-08-18.

Background

The article is an SEC Form 4 insider transaction disclosure for Shoulder Innovations, Inc. (SI), reporting an open-market sale by the COO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$SINeutralMedium confidence
Context

Shoulder Innovations COO Ahearn Matthew Fraser sold about 22,500 shares in open-market trades for roughly $464,805, per a new SEC Form 4 filed today.

Expected impact

Near-term impact likely limited; any reaction would be more about optics of insider selling than new company fundamentals.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan and an open-market sale, which typically reduces the signal strength versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so the market may overreact to the headline optics.

Key entities

  • Shoulder Innovations, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Ahearn Matthew Fraser

    Chief Operating Officer and reporting insider who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan that typically reduces interpretive signal from insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.

$SIMed

Siemens to acquire EDA software firm Precision Innovations

Siemens said it signed an agreement to acquire privately held US EDA software firm Precision Innovations. Siemens said the deal will add AI-powered chip planning and early design exploration using the OpenROAD framework to help semiconductor teams optimize power, performance and area, reduce iterations, and speed SoC feasibility analysis and time to market.

$SIMedAI 8/10

SHOULDER INNOVATIONS, INC. (SI): Results of Operations and Financial Condition

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook Generates First Half 2026 Revenue Growth of 60% Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commerc

$SIMed

Siemens to acquire chip design firm Precision Innovations

Siemens said it agreed to acquire privately held Precision Innovations Inc., an electronic design automation firm. Siemens will add Precision’s AI-powered chip planning tools to its EDA portfolio to help semiconductor teams evaluate design tradeoffs earlier in system-on-a-chip development, aiming to improve power, performance and area outcomes and speed time to production.